Eliem Therapeutics ETX-155 update; Phase 2a MDD on track for Q1 2023; cash $129.8M

Climb Bio, Inc.

Cash, cash equivalents and investments of $129.8M as of Sept 30, 2022 (includes $6.2M tax reimbursements); funds operations into 2025.
ETX-155 60mg single-dose exposures in Phase 1 PK trial consistent with prior trials; low PSE exposures within previously reported variability.
Company to evaluate 75mg repeat dose in ongoing Phase 1 PK trial; final results expected Q4 2022.
Phase 2a MDD trial to initiate Q1 2023; topline data mid-2024. PSE trial not reinitiated; FOS development continues.
Kv7 program: two pre-candidates scaling up for IND-enabling studies Q1 2023; Phase 1 studies H1 2024. GAD program discontinued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.